Cronos Group Inc. CRON PHARMA
Company Overview
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
Why Investors Should Care
Revenue has grown at a 42.8% CAGR over the past five years.
Trades at a P/E of 16.7, below the sector median of 24.8.
Maintains a net profit margin of 39.1%.
Carries low leverage with a debt-to-equity ratio of 0.12.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $146.59M (+24.6% YoY); net profit $-9.45M.
- Trailing 12 Months Year-on-year growth — revenue +58.4%, earnings -123.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 42.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 42.77% |
| 1 Year: | 58.40% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -123.00% |
Stock Price Performance
| 1 Year: | +21.56% |
| 6 Months: | +26.39% |
| 3 Months: | +14.98% |
| 1 Month: | +2.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.32 · Neutral
P/E of 16.74 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 39.1%.
- Compounding revenue at 42.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CRON Cronos Group Inc. PHARMA | 3.18 | 16.74 | $1.17B | 0.00% | -1.51% | 7.05% | 42.77% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.00M | 7.65M | 5.79M | 8.43M | 9.88M | 11.36M | 12.61M | 15.62M | 20.41M | 25.03M | 21.60M | 20.41M | 19.50M | 19.02M | 24.81M | 25.29M | 27.76M | 34.26M | 32.26M | 33.45M | 36.34M | 45.21M | 53.01M |
| Gross Profit | 1.55M | 4.09M | -3.14M | -6.48M | -2.92M | -1.54M | -2.96M | -15.78M | -730.00K | 6.93M | 4.32M | 3.14M | 2.93M | 3.10M | 3.97M | 4.48M | 6.30M | 3.61M | 13.73M | 14.50M | 18.33M | 19.15M | 28.45M |
| Operating Income | -10.13M | -16.75M | -30.70M | -45.06M | -34.71M | -41.17M | -45.20M | -296.35M | -56.41M | -36.05M | -25.30M | -27.33M | -20.77M | -20.62M | -21.77M | -15.95M | -15.56M | -33.66M | -4.07M | -5.32M | -503.00K | -1.83M | 7.40M |
| Net Income | 314.09M | 186.00M | 604.41M | 76.04M | -106.98M | 69.03M | -161.31M | -179.07M | 77.92M | -32.64M | -20.22M | -36.99M | -19.17M | -8.36M | -1.64M | -2.24M | -8.76M | 8.35M | 6.12M | -39.71M | 25.96M | 13.75M | 32.09M |
| Diluted EPS | 0.33 | 0.16 | 1.62 | 0.20 | -0.31 | 0.19 | -0.44 | - | - | - | -0.05 | -0.10 | -0.05 | -0.02 | 0.00 | -0.01 | -0.02 | 0.02 | 0.02 | -0.10 | 0.07 | 0.04 | 0.09 |
| R&D Expense | 1.17M | 2.30M | 2.60M | 4.59M | 3.63M | 4.73M | 5.10M | 5.20M | 6.47M | 4.04M | 4.19M | 2.54M | 2.04M | 1.11M | 1.25M | 997.00K | 962.00K | 1.24M | 793.00K | 929.00K | 1.34M | 1.41M | 1.22M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12.12M | 23.75M | 46.72M | 64.56M | 86.75M | 87.24M | 117.61M | 146.59M |
| Gross Profit | 6.21M | -17.60M | -25.83M | -17.59M | 15.44M | 11.91M | 25.20M | 62.76M |
| Operating Income | -20.45M | -153.32M | -219.39M | -291.97M | -111.43M | -84.80M | -76.53M | -17.39M |
| Net Income | -21.64M | 1.17B | -73.14M | -396.11M | -168.73M | -73.96M | 41.08M | -9.45M |
| Diluted EPS | -0.12 | 3.33 | -0.21 | -1.07 | -0.45 | -0.19 | 0.11 | -0.02 |
| R&D Expense | 1.81M | 12.15M | 20.37M | 21.84M | 13.13M | 5.84M | 4.23M | 4.45M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 183.47M | 2.09B | 1.93B | 1.40B | 1.21B | 1.14B | 1.17B | 1.20B |
| Total Equity | 63.73M | 148.55M | 1.75B | 1.71B | 1.34B | 1.14B | 1.10B | 1.06B | 1.09B |
| Cash & Equivalents | - | - | 1.20B | 1.08B | 886.97M | 764.64M | 669.29M | 858.80M | 791.79M |
| Total Liabilities | - | - | 341.41M | 217.51M | 63.46M | 72.05M | 44.14M | 55.33M | 54.18M |
| Current Liabilities | - | - | 332.89M | 206.83M | 54.37M | 68.12M | 41.40M | 49.70M | 48.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.52M | -131.19M | -144.87M | -153.62M | -88.95M | -42.84M | 18.84M | 25.87M |
| Investing Cash Flow | -93.91M | -603.27M | 20.15M | -28.90M | -1.84M | -59.50M | 175.15M | -76.56M |
| Financing Cash Flow | 122.11M | 1.86B | -3.05M | -13.44M | -2.90M | -1.03M | -1.23M | -19.91M |
| Capital Expenditure | -88.31M | -38.66M | -31.41M | -11.14M | -3.45M | -2.50M | -12.41M | -25.72M |
| Free Cash Flow | -95.83M | -169.86M | -176.28M | -164.76M | -92.40M | -45.34M | 6.43M | 149.00K |
| Share Buybacks | - | - | - | - | - | 0 | 0 | 9.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 51.3% | -74.1% | -55.3% | -27.3% | 17.8% | 13.7% | 21.4% | 42.8% |
| Operating Margin % | -168.7% | -645.5% | -469.6% | -452.2% | -128.4% | -97.2% | -65.1% | -11.9% |
| Net Margin % | -178.5% | 4,911.6% | -156.5% | -613.5% | -194.5% | -84.8% | 34.9% | -6.4% |
| ROE % | -14.6% | 66.7% | -4.3% | -29.6% | -14.8% | -6.7% | 3.9% | -0.9% |
| ROCE % | - | -8.7% | -12.8% | -21.7% | -9.7% | -7.7% | -6.9% | -1.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Shaw D.E. & Co., Inc. | 2.40% | 8.84M | $29.62M |
| 2 | Chescapmanager LLC | 2.16% | 7.94M | $26.61M |
| 3 | Tidal Investments LLC | 1.02% | 3.77M | $12.62M |
| 4 | Dimensional Fund Advisors LP | 0.83% | 3.05M | $10.21M |
| 5 | Arrowstreet Capital, Limited Partnership | 0.54% | 1.99M | $6.68M |
| 6 | Renaissance Technologies, LLC | 0.47% | 1.74M | $5.84M |
| 7 | Mackenzie Financial Corporation | 0.43% | 1.60M | $5.35M |
| 8 | CIBC World Market, Inc. | 0.38% | 1.38M | $4.63M |
| 9 | MMCAP International, Inc. SPC | 0.27% | 999.49K | $3.35M |
| 10 | Quinn Opportunity Partners, LLC | 0.26% | 969.03K | $3.25M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CRON
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOOXpXWkM2QXlrcTJtNmJrNDJIa3VuaGxBRks5Snk4dmQ0eXZobUxOVTZCR2FrZlIwdEhsQ2RKc2JGMDloQjZaOTRzOERQSnBkMTZ4cFhTdS05ejQ0eHF4NE03YmlQV0NsTzludGxUNFRqaUpfUld6RHpnUDFOS0xQenl3S3JPVTdUUmgwcF…
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying? - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOUHlKaU1wMG5STUt3SXc5bmJTaHQwUmZNaGN6U085aWFQWTQ2eU9zZDhlbG9rWVN0bFZTcGRpM25JQXkyMzhvME90bXpTM3I4LU9XR1V1akRGT21JWm9IRW5SalVuWi1JMTNHM0pWYzhPZlJ3M2lWRDZlOExYTDdCeTgtR0F1dWFGLU9VbF…
Could Cronos Group Inc. (TSX:CRON) Drive Cannabis Stock Interest? - Kalkine Media
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOSWt2UDhsTEtBTkl1ZG5nUk05dUhUWWFVQWlUSVZQWTluWG1mOVQ3ZUdYZzFZWHA5bUgxQno1alU1Tm1HUVN2LUxvQTRaVzV5S2Y4YVBjVk5salN5ZzByNjZ5ekpQb3pmSFZaOFRCLUVaclBucjkxMHRlc1AzMUY3ellXN1ZQaHhiM0N6Xz…
A cannabis brand led Canada’s vape sales with 11% in June. Spinach adds a new gummy. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPVk1EUGhCN01Bb3Rza2ZJZ2JBaG53ZTRsNm85M0FvUzQ1LWI4MEhKd3JwZFZ3bFItemMwdXdFSUxXcjJLRmhPcmF6TjBUNzY4OWlFQWFBNUZfVGNqQ0pYdHd1NGJSUTlsSEJZY01FYlJkRGFTZkU5SEt2ZU9fRHVXenVIWnVuMV9UNW9vWW…
Is Cronos Group’s (TSX:CRON) Live Resin Push a Turning Point for Its Brand Strategy? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNTzUzME4ydlpvbWlobDhHSndYaWNzU1Q0NjBuU1M2QUQ2azRRV2tSVW15S1VDbnRpN3ZzaTRUYlRPY1dHN2g4a2pacXNQOVVGZjJmSVFpQVpQaU1Vd1hCZGE0Q0hVZVFvelR6NkNlV2R6akt0ZHI5Ym5fZGFTWkFVWUgxYXBYWVFOMWptbW…
Cronos Group Inc (CRON): Why This Canadian-Listed Stock Could Be One to Watch in September - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQUENncFk2VDY0WVRQdGl6RkJ4WEMxQ1JIRm5aNDM0LWJQU0syeVNlTllEQjU2TFBYVTZibFp5WGNiS0tNOGhpM1JDVW5SNml2S0p6YzF3c0owZEZPRGxKaU9iUXBmMkRZZmg2NlNLREd5N0k5ODBiMTlVdW14WVVwemZSbExqbk9FRUlLTE…
CRON — Frequently Asked Questions
What is the current share price of Cronos Group Inc. (CRON)?
As of 2026-09-19 21:16 PDT, Cronos Group Inc. (CRON) trades at $3.18 on NasdaqGM. Its 52-week range is $2.30 to $3.55.
What is the market capitalisation of CRON?
Cronos Group Inc. (CRON) has a market capitalisation of $1.17B on NasdaqGM.
What is the P/E ratio of CRON?
CRON trades at a trailing price-to-earnings (P/E) ratio of 16.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.09.
What is the return on equity (ROE) of CRON?
CRON has a return on equity (ROE) of 7.05%. Its return on capital employed (ROCE) is -1.51%.
Is CRON a good stock to buy?
This page provides a data-driven analysis of Cronos Group Inc. (CRON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.